Sangamo price target raised to $9 from $3 at Barclays

Barclays raised the firm’s price target on Sangamo (SGMO) to $9 from $3 and keeps an Overweight rating on the shares post the Q3 report. Following the recent announcement of an accelerated approval pathway alignment with the FDA, the Q3 call focused on the Fabry program’s path forward, with partnership discussions in late stage, the analyst tells investors in a research note. The firm sees a high probability of positive data in Q3 of 2025 and FDA approval in 2026, and expects a deal announcement in the near term.